Taichi Isobe

2.9k total citations
34 papers, 490 citations indexed

About

Taichi Isobe is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Taichi Isobe has authored 34 papers receiving a total of 490 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 13 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Taichi Isobe's work include Cancer Cells and Metastasis (9 papers), Cancer Immunotherapy and Biomarkers (7 papers) and MicroRNA in disease regulation (3 papers). Taichi Isobe is often cited by papers focused on Cancer Cells and Metastasis (9 papers), Cancer Immunotherapy and Biomarkers (7 papers) and MicroRNA in disease regulation (3 papers). Taichi Isobe collaborates with scholars based in Japan, United States and France. Taichi Isobe's co-authors include Eishi Baba, Hitoshi Kusaba, Koichi Akashi, Yohei Shimono, Piero Dalerba, Hiroshi Ariyama, Shuji Arita, Shaheen S. Sikandar, Maider Zabala and Patrick O. Brown and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Taichi Isobe

27 papers receiving 487 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Taichi Isobe Japan 12 325 209 186 57 51 34 490
Nicole P. Ho Hong Kong 6 265 0.8× 213 1.0× 137 0.7× 65 1.1× 46 0.9× 9 453
Yongfeng Wu China 10 370 1.1× 293 1.4× 181 1.0× 67 1.2× 92 1.8× 13 558
Zhongcheng Huang China 12 294 0.9× 293 1.4× 177 1.0× 41 0.7× 41 0.8× 23 481
Xiaojian Ni China 13 263 0.8× 185 0.9× 201 1.1× 54 0.9× 60 1.2× 34 475
Suyu Miao China 8 256 0.8× 210 1.0× 99 0.5× 41 0.7× 58 1.1× 11 428
Fanfei Kong China 15 422 1.3× 378 1.8× 151 0.8× 49 0.9× 43 0.8× 26 626
Hongjuan Xu China 9 233 0.7× 155 0.7× 88 0.5× 61 1.1× 68 1.3× 21 372
Noga Bloushtain-Qimron United States 7 258 0.8× 130 0.6× 137 0.7× 52 0.9× 49 1.0× 8 375
Na Zhou China 14 266 0.8× 223 1.1× 156 0.8× 99 1.7× 55 1.1× 33 488
Renba Liang China 10 212 0.7× 150 0.7× 145 0.8× 57 1.0× 53 1.0× 14 400

Countries citing papers authored by Taichi Isobe

Since Specialization
Citations

This map shows the geographic impact of Taichi Isobe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Taichi Isobe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Taichi Isobe more than expected).

Fields of papers citing papers by Taichi Isobe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Taichi Isobe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Taichi Isobe. The network helps show where Taichi Isobe may publish in the future.

Co-authorship network of co-authors of Taichi Isobe

This figure shows the co-authorship network connecting the top 25 collaborators of Taichi Isobe. A scholar is included among the top collaborators of Taichi Isobe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Taichi Isobe. Taichi Isobe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Isobe, Taichi, Hirofumi Ohmura, Toshihiro Yamaguchi, et al.. (2025). Metastatic urachal carcinoma treated with trifluridine/tipiracil and bevacizumab: a case report. International Cancer Conference Journal. 14(3). 280–288.
2.
Yamaguchi, Toshihiro, Kenji Tsuchihashi, Sayaka Ueno, et al.. (2025). Efficacy of pembrolizumab in microsatellite-stable, tumor mutational burden-high metastatic colorectal cancer: genomic signatures and clinical outcomes. ESMO Open. 10(1). 104108–104108. 3 indexed citations
3.
Nishimura, Toshinobu, Laura Amaya, Jonas L. Fowler, et al.. (2025). Development of iPSC-derived T cells targeting EGFR neoantigens in non-small cell lung cancer. Molecular Therapy — Methods & Clinical Development. 33(3). 101517–101517.
4.
Yamaguchi, Toshihiro, Hiroshi Ariyama, Hirofumi Ohmura, et al.. (2025). Elucidation of the mechanism of carcinogenic transformation of human gastric epithelial cells in atrophic gastritis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1871(6). 167843–167843.
5.
Tanizaki, Junko, Koji Matsumoto, Toshiki Masuishi, et al.. (2024). Phase Ia/Ib trial on the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M).. Journal of Clinical Oncology. 42(16_suppl). 3025–3025. 2 indexed citations
6.
Yamaguchi, Toshihiro, Mamoru Ito, Taichi Isobe, et al.. (2024). Impact of Genomic Alterations on Efficacy of Trastuzumab Deruxtecan Against Human Epidermal Growth Factor Receptor-2–Positive Advanced Gastric Cancer. JCO Precision Oncology. 8(8). e2300681–e2300681. 2 indexed citations
7.
Matsumura, Takashi, Kenji Tsuchihashi, Takeo Yamamoto, et al.. (2024). Lymphoproliferative Disorder in an Esophageal Cancer Patient Treated with Pembrolizumab. Internal Medicine. 64(11). 1728–1732. 2 indexed citations
8.
Ohmura, Hirofumi, Mamoru Ito, Kenji Tsuchihashi, et al.. (2024). Treatment of malignant primary cardiac tumors requires attention to cardiovascular complications: a single-center, retrospective study. Japanese Journal of Clinical Oncology. 55(2). 113–122.
9.
Yamaguchi, Toshihiro, Hirofumi Ohmura, Mamoru Ito, et al.. (2023). Preferential B cell differentiation by combined immune checkpoint blockade for renal cell carcinoma is associated with clinical response and autoimmune reactions. Cancer Immunology Immunotherapy. 72(11). 3543–3558. 5 indexed citations
10.
Nakano, Michitaka, Yoshikane Kikushige, Taichi Isobe, et al.. (2023). RHAMM marks proliferative subpopulation of human colorectal cancer stem cells. Cancer Science. 114(7). 2895–2906. 7 indexed citations
11.
Ito, Mamoru, Michitaka Nakano, Hiroshi Ariyama, et al.. (2022). Macrophages are primed to transdifferentiate into fibroblasts in malignant ascites and pleural effusions. Cancer Letters. 532. 215597–215597. 13 indexed citations
12.
Hisamori, Shigeo, Sanjay Koul, Takanori Hayashi, et al.. (2022). Upregulation of BMI1-suppressor miRNAs (miR-200c, miR-203) during terminal differentiation of colon epithelial cells. Journal of Gastroenterology. 57(6). 407–422. 5 indexed citations
13.
Isobe, Taichi, Qingjiang Hu, Takanori Hayashi, et al.. (2019). miR-221 Targets QKI to Enhance the Tumorigenic Capacity of Human Colorectal Cancer Stem Cells. Cancer Research. 79(20). 5151–5158. 54 indexed citations
14.
Shimono, Yohei, et al.. (2016). Organoid Culture of Human Cancer Stem Cells. Methods in molecular biology. 1576. 23–31. 11 indexed citations
15.
Nio, Kenta, Shuji Arita, Taichi Isobe, et al.. (2015). Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy. Cancer Chemotherapy and Pharmacology. 75(4). 829–835. 14 indexed citations
16.
Isobe, Taichi, Shigeo Hisamori, Daniel J. Hogan, et al.. (2014). miR-142 regulates the tumorigenicity of human breast cancer stem cells through the canonical WNT signaling pathway. eLife. 3. 155 indexed citations
17.
Isobe, Taichi, Keita Uchino, Hiroshi Ariyama, et al.. (2014). Analysis of adverse events of bevacizumab-containing systemic chemotherapy for metastatic colorectal cancer in Japan.. PubMed. 34(4). 2035–40. 11 indexed citations
18.
Tsuchihashi, Kenji, Keita Uchino, Tsuyoshi Shirakawa, et al.. (2012). Systemic chemotherapy for metastatic non-mucinous appendiceal adenocarcinoma: a case report and literature review. International Cancer Conference Journal. 2(1). 36–40.
19.
Shibata, Yoshihiro, Eishi Baba, Hiroshi Ariyama, et al.. (2010). Irinotecan-based combination chemotherapy for metastatic small intestinal adenocarcinoma. Oncology Letters. 1(3). 423–426. 1 indexed citations
20.
Makiyama, Akitaka, Keita Uchino, Yoshihiro Shibata, et al.. (2009). Schedule-dependent synergistic interaction between gemcitabine and oxaliplatin in human gallbladder adenocarcinoma cell lines. Anti-Cancer Drugs. 20(2). 123–130. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicole P. Ho Breakdown of academic impact, for papers by Yongfeng Wu Breakdown of academic impact, for papers by Zhongcheng Huang Breakdown of academic impact, for papers by Xiaojian Ni Breakdown of academic impact, for papers by Suyu Miao Breakdown of academic impact, for papers by Fanfei Kong Breakdown of academic impact, for papers by Hongjuan Xu Breakdown of academic impact, for papers by Noga Bloushtain-Qimron Breakdown of academic impact, for papers by Na Zhou Breakdown of academic impact, for papers by Renba Liang
Rankless by CCL
2026